Equibles does not estimate personal net worth.
Get an email with a short summary when GoodRx Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get GDRX alertsKarsten Voermann is recorded as CFO at GoodRx Holdings, Inc. (GDRX). The newest filing on record that lists Karsten Voermann as CFO at GoodRx Holdings, Inc. (GDRX) is dated April 29, 2026. GoodRx Holdings, Inc. reported in an 8-K filed January 13, 2025 that Karsten Voermann resigned as Chief Financial Officer, effective January 17, 2025. The proxy statement of GoodRx Holdings, Inc. reports total compensation of $280,256 for Karsten Voermann in fiscal 2025, including a base salary of $22,212. Disclosed compensation is on record for 5 fiscal years. Karsten Voermann has spoken on 16 earnings calls across 1 company, most recently for GoodRx Holdings, Inc. on November 7, 2024. GoodRx Holdings, Inc. is classified in the Health Information Services industry within the Healthcare sector. Other leadership on record at GoodRx Holdings, Inc. includes Scott Wagner (CEO, Chairman and Board Member), Wendy Barnes (CEO and Board Member), Trevor Bezdek (Chairman) and 7 others.
“On January 7, 2025, Karsten Voermann submitted his resignation as Chief Financial Officer of GoodRx Holdings, Inc. (the "Company"), effective January 17, 2025 (the "Effective Date") for personal reasons.”
“I’ll review our third quarter financial results before turning to guidance. During the third quarter, revenue and adjusted revenue were at the midpoint of the guidance we provided on our second quarter earnings call in August, and adjusted EBITDA margin was higher than we anticipated.”
“I'll review our second quarter financial results before turning to guidance.”
“I'll speak briefly to our 1Q '24 financial results before turning to guidance. In summary, during the first quarter, revenue and adjusted revenue were in the upper end of the guidance range we provided on our Q4 earnings call in February, and adjusted EBITDA margin was a beat, exceeding the guidance we provided.”
“I'll speak briefly to our 4Q '23 financial results, which were consistent with the preliminary Q4 results we announced in January before turning to guidance.”
“I'll first speak to our Q3 2023 financial results before turning to guidance. In summary, during the third quarter, adjusted revenue, adjusted EBITDA, and adjusted EBITDA margin were each in the upper end of our ranges.”
Start not stated–present
Last confirmed April 29, 2026
Start not stated–2025-01-17
Health Information Services · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GoodRx Holdings, Inc. (GDRX) | Former Chief Financial Officer | $22,212 | $280,256 |
| 2024 | GoodRx Holdings, Inc. (GDRX) | Chief Financial Officer | $450,000 | $5,836,601 |
| 2023 | GoodRx Holdings, Inc. (GDRX) | Chief Financial Officer | $450,000 | $902,242 |
| 2022 | GoodRx Holdings, Inc. (GDRX) | Chief Financial Officer | $439,000 | $5,235,060 |
| 2021 | GoodRx Holdings, Inc. (GDRX) | Chief Financial Officer | $428,000 | $520,970 |
